Preclinical pharmacokinetics and tolerability of a novel meglumine‐based parenteral solution of topiramate and topiramate combinations for treatment of status epilepticus
Epilepsia · 2023
DOI: 10.1111/epi.17520 ↗Kurz gefasst
Fachartikel in der Zeitschrift Epilepsia, 2023. Verfasst von Chris Rundfeldt und 9 weiteren Autor:innen. Beteiligte Einrichtung: PrevEp Inc., Bethesda, Maryland, USA. Hauptthemen laut MEDLINE: Anticonvulsants, Status Epilepticus. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objective
For an antiseizure medication (ASM) to be effective in status epilepticus (SE), the drug should be administered intravenously (i.v.) to provide quick access to the brain. However, poor aqueous solubility is a major problem in the development of parenteral drug solutions. Given its multiple mechanisms of action, topiramate (TPM) is a promising candidate for the treatment of established or refractory SE, as supported by clinical studies using nasogastric tube TPM administration. However, TPM is not clinically available as a solution for i.v. administration, which hampers its use in the treatment of SE. Here, we describe a novel easy‐to‐use and easy‐to‐prepare i.v. TPM formulation using the U.S. Food and Drug Administration (FDA)–approved excipient meglumine.
Methods
During formulation development, we compared the solubility of TPM in bi‐distilled water with vs without a range of meglumine concentrations. Furthermore, the solubility of combinations of TPM and levetiracetam and TPM, levetiracetam, and atorvastatin in aqueous meglumine concentrations was determined. Subsequently, the pharmacokinetics and tolerability of meglumine‐based solutions of TPM and TPM combinations were evaluated in rats, including animals following fluid percussion injury or pilocarpine‐induced SE.
Results
The amino sugar meglumine markedly enhances the aqueous solubility of TPM. A comparison with data on dissolving TPM using sulfobutylether‐β‐cyclodextrin (Captisol) demonstrates that meglumine is much more effective for dissolving TPM. Furthermore, meglumine can be used to prepare drug cocktails where TPM is co‐administered with another ASM for SE treatment. The tolerability studies of the meglumine‐based TPM solution and meglumine‐based TPM combinations in normal rats and the rat fluid percussion injury and pilocarpine‐induced SE models demonstrate excellent tolerability of the novel drug solutions. Preclinical studies on antiseizure efficacy in the SE model are underway. Significance In conclusion, the novel meglumine‐based solution of TPM presented here may be well suited for clinical development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- PrevEp Inc., Bethesda, Maryland, USA.
- Mid-Atlantic Epilepsy and Sleep Center, Bethesda, Maryland, USA.
- Department of Neurosurgery, Robert Wood Johnson & New Jersey Medical Schools, Rutgers University, Piscataway, New Jersey, USA.
- Division of Epilepsy and Neurophysiology, Department of Neurology, Boston Children's Hospital, Boston, Massachusetts, USA.
- FM Kirby Center for Neurobiology, Boston Children's Hospital, Boston, Massachusetts, USA.
- Department of Neurological Surgery, University of Washington, Seattle, Washington, USA.
ORCID-Profile: Pavel Klein, Wolfgang Löscher
Zitieren
APA
Rundfeldt, C., Klein, P., Boison, D., Rotenberg, A., D'Ambrosio, R., Eastman, C., Purnell, B., Murugan, M., Goodkin, H. P., & Löscher, W. (2023). Preclinical pharmacokinetics and tolerability of a novel meglumine‐based parenteral solution of topiramate and topiramate combinations for treatment of status epilepticus. Epilepsia. https://doi.org/10.1111/epi.17520
Vancouver
Rundfeldt C, Klein P, Boison D, Rotenberg A, D'Ambrosio R, Eastman C, et al. Preclinical pharmacokinetics and tolerability of a novel meglumine‐based parenteral solution of topiramate and topiramate combinations for treatment of status epilepticus. Epilepsia. 2023. doi:10.1111/epi.17520
BibTeX
@article{Rundfeldt2023,
author = {Rundfeldt, Chris and Klein, Pavel and Boison, Detlev and Rotenberg, Alexander and D'Ambrosio, Raimondo and Eastman, Cliff and Purnell, Benton and Murugan, Madhuvika and Goodkin, Howard P and Löscher, Wolfgang},
title = {Preclinical pharmacokinetics and tolerability of a novel meglumine‐based parenteral solution of topiramate and topiramate combinations for treatment of status epilepticus},
journal = {Epilepsia},
year = {2023},
doi = {10.1111/epi.17520}
}
EUVIMED